Allogene Therapeutics said the FDA granted RMAT and Fast Track designations to cema-cel, its investigational off-the-shelf CAR-T therapy for large B-cell lympho

Allogene Therapeutics said the FDA granted RMAT and Fast Track designations to cema-cel, its investigational off-the-shelf CAR-T therapy for large B-cell lymphoma. The dual status could speed development and review as Allogene advances the ALPHA3 trial.